Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEHAW
Aesther Healthcare Acquisition
$0.01
+5.3%
$0.02
$0.06
$0.33
N/AN/A34,287 shs56,579 shs
NexImmune, Inc. stock logo
NEXI
NexImmune
$0.05
$0.00
$7.05
N/A1.987,749 shsN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
$7.22
-1.5%
$7.76
$4.11
$25.00
N/AN/A82,858 shs19,966 shs
(ROSG) stock logo
ROSG
(ROSG)
$0.43
$0.43
$0.23
$2.75
N/AN/A81,512 shs169,599 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEHAW
Aesther Healthcare Acquisition
+5.34%+366.67%-53.02%-57.06%-88.80%
NexImmune, Inc. stock logo
NEXI
NexImmune
0.00%0.00%0.00%-99.90%-100.00%
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
0.00%-3.60%+20.53%+721,999,900.00%+721,999,900.00%
(ROSG) stock logo
ROSG
(ROSG)
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/AN/AN/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
(ROSG) stock logo
ROSG
(ROSG)
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEHAW
Aesther Healthcare Acquisition
0.00
N/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
0.00
N/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
0.00
N/AN/AN/A
(ROSG) stock logo
ROSG
(ROSG)
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/A$3.32 per shareN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
$79.99KN/AN/AN/AN/AN/A
(ROSG) stock logo
ROSG
(ROSG)
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEHAW
Aesther Healthcare Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
-$32.34M-$18.54N/AN/AN/AN/A-534.32%-213.72%N/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
(ROSG) stock logo
ROSG
(ROSG)
N/AN/A0.00N/AN/AN/AN/AN/A

Latest ROSG, AEHAW, NTHI, and NEXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/A-$2.10N/A-$2.10N/A$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/AN/AN/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/AN/AN/AN/A
(ROSG) stock logo
ROSG
(ROSG)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/A
NexImmune, Inc. stock logo
NEXI
NexImmune
N/A
0.66
0.66
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/AN/A
(ROSG) stock logo
ROSG
(ROSG)
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AEHAW
Aesther Healthcare Acquisition
N/A
NexImmune, Inc. stock logo
NEXI
NexImmune
9.85%
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/A
(ROSG) stock logo
ROSG
(ROSG)
22.80%

Insider Ownership

CompanyInsider Ownership
AEHAW
Aesther Healthcare Acquisition
N/A
NexImmune, Inc. stock logo
NEXI
NexImmune
14.90%
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/A
(ROSG) stock logo
ROSG
(ROSG)
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AEHAW
Aesther Healthcare Acquisition
2N/AN/ANot Optionable
NexImmune, Inc. stock logo
NEXI
NexImmune
61.40 million1.19 millionNot Optionable
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
8N/AN/AN/A
(ROSG) stock logo
ROSG
(ROSG)
N/AN/AN/ANot Optionable

Recent News About These Companies

Rosetta Genomics Ltd ROSGQ
Genetics and Genomics Virtual Event Series 2016
Rosetta Stone Military Discount
Apple Mac Studio (M2 Ultra, 2023)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.01 +0.00 (+5.26%)
As of 05/23/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

NexImmune stock logo

NexImmune NASDAQ:NEXI

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Neonc Technologies stock logo

Neonc Technologies NASDAQ:NTHI

$7.22 -0.11 (-1.50%)
As of 05/23/2025 04:00 PM Eastern

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

(ROSG) stock logo

(ROSG) NASDAQ:ROSG

Rosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. The company develops and commercializes new diagnostic tests based on various genomics markers, including DNA, microRNA and protein biomarkers and using various technologies, including, qPCR, microarrays, next generation sequencing and fluorescence in situ hybridization. It offers proprietary microRNA technologies, such as Rosetta Cancer Origin, mi-KIDNEY, and RosettaGX Reveal Test. The company was founded by Isaac Bentwich on March 9, 2000 and is headquartered in Rehovot, Israel.